Combination of phosphorylated and truncated EGFR correlates with higher tumor and nodal stage in head and neck cancer

Cancer Investigation

Volumn 28, Issue 10, 2010, Pages 1054-1062

  Keller, James ^a   Shroyer, Kenneth R ^a   Batajoo, Shishir K ^a   Zhao, Hong Ling ^a   Dong, Li Ming ^a   Hayman, Michael J ^a   Chan, Edward L ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

EGFRvIII; Head and neck squamous cell carcinomas; Phosphorylated EGFR; Truncated EGFR; Tyrosine kinase receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA;

AGED; CARCINOMA, SQUAMOUS CELL; DNA MUTATIONAL ANALYSIS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 78649312092     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2010.512602     Document Type: Article

References (24)

1. Kolibaba, K. S.; Druker, B. J. Protein tyrosine kinases and cancer. Biochim Biophys Acta 1997 Dec. 9, 1333 (3), F217-F248.
2. Rubin Grandis, J.; Melhem, M. F.; Gooding, W. E.; Day, R.; Holst, V. A.; Wagener, M. M.; Drenning, S. D.; Tweardy, D. J. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998 Jun. 3, 90 (11), 824-832.
3. Ang, K. K.; Berkey, B. A.; Tu, X.; Zhang, H. Z.; Katz, R.; Hammond, E. H.; Fu, K. K.; Milas, L. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002 Dec. 15, 62 (24), 7350-7356.
4. Kong, A.; Leboucher, P.; Leek, R.; Calleja, V.; Winter, S.; Harris, A.; Parker, P. J.; Larijani, B. Prognostic value of an activation state marker for epidermal growth factor receptor in tissue microarrays of head and neck cancer. Cancer Res 2006 Mar. 1, 66 (5), 2834-2843.
5. Hiraishi, Y.; Wada, T.; Nakatani, K.; Negoro, K.; Fujita, S. Immunohistochemical expression of EGFR and p-EGFR in oral squamous cell carcinomas. Pathol Oncol Res 2006, 12 (2), 87-91.
6. Sok, J. C.; Coppelli, F. M.; Thomas, S. M.; Lango, M. N.; Xi, S.; Hunt, J. L.; Freilino, M. L.; Graner, M. W.; Wikstrand, C. J.; Bigner, D. D.; Gooding, W. E.; Furnari, F. B.; Grandis, J. R. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006 Sep. 1, 12 (17), 5064-5073.
7. Slamon, D. J.; Godolphin, W.; Jones, L. A.; Holt, J. A.; Wong, S. G.; Keith, D. E.; Levin, W. J.; Stuart, S. G.; Udove, J.; Ullrich, A.; Press, M. F. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989 May 12, 244 (4905), 707-712.
8. Agazie, Y. M.; Hayman, M. J. Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling. Mol Cell Biol 2003 Nov, 23 (21), 7875-7886.
9. Bode, B.; Frigerio, S.; Behnke, S.; Senn, B.; Odermatt, B.; Zimmermann, D. R.; Moch, H. Mutations in the tyrosine kinase domain of the EGFR gene are rare in synovial sarcoma. Mod Pathol 2006 Apr, 19 (4), 541-547.
10. Hama, T.; Yuza, Y.; Saito, Y.; Ou, J.; Kondo, S.; Okabe, M.; Yamada, H.; Kato, T.; Moriyama, H.; Kurihara, S.; Urashima, M. Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma. Oncologist 2009 Sep, 14 (9), 900-908.
11. Quon, H.; Liu, F. F.; Cummings, B. J. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck 2001 Feb, 23 (2), 147-159.
12. Ford, A. C.; Grandis, J. R. Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 2003 Jan, 25 (1), 67-73.
13. Etienne, M. C.; Pivot, X.; Formento, J. L.; Bensadoun, R. J.; Formento, P.; Dassonville, O.; Francoual, M.; Poissonnet, G.; Fontana, X.; Schneider, M.; Demard, F.; Milano, G. A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil. Br J Cancer 1999 Apr, 79 (11-12), 1864-1869.
14. Cohen, E. E.; Rosen, F.; Stadler, W. M.; Recant, W.; Stenson, K.; Huo, D.; Vokes, D. E. Phase-II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003 May 15, 21 (10), 1980-1987.
15. Soulieres, D.; Senzer, N. N.; Vokes, E. E.; Hidalgo, M.; Agarwala, S. S.; Siu, L. L. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004 Jan 1, 22 (1), 77-85.
16. Baselga, J.; Trigo, J. M.; Bourhis, J.; Tortochaux, J.; Cortes-Funes, H.; Hitt, R.; Gascon, P.; Amellal, N.; Harstrick, A.; Eckhardt, A. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005 Aug. 20, 23 (24), 5568-5577.
17. Bonner, J. A.; Harari, P. M.; Giralt, J.; Azarnia, N.; Shin, D. M.; Cohen, R. B.; Jones, C. U.; Sur, R.; Raben, D.; Jassem, J.; Ove, R.; Kies, M. S.; Baselga, J.; Youssoufian, H.; Amellal, N.; Rowinsky, E. K.; Ang, K. K. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006 Feb. 9, 354 (6), 567-578.
18. Pedersen, M. W.; Meltorn, M.; Damstrup, L.; Poulsen, H. S. The type-III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol 2001 Jun, 12 (6), 745-760.
19. Ji, H.; Zhao, X.; Yuza, Y.; Shimamura, T.; Li, D.; Protopopov, A.; Jung, B. L.; McNamara, K.; Xia, H.; Glatt, K. A.; Thomas, R. K.; Sasaki, H.; Horner, J. W.; Eck, M.; Mitchell, A.; Sun, Y.; Al-Hashem, R.; Bronson, R. T.; Rabindran, S. K.; Discafani, C. M.; Maher, E.; Shapiro, G. I.; Meyerson, M.; Wong, K. K. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci USA 2006 May 16, 103 (20), 7817-7822.
20. Frederick, L.; Wang, X. Y.; Eley, G.; James, C. D. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000 Mar. 1, 60 (5), 1383-1387.
21. Frederick, L.; Eley, G.; Wang, X. Y.; James, C. D. Analysis of genomic rearrangements associated with EGRFvIII expression suggests involvement of Alu repeat elements. Neuro Oncol 2000 Jul, 2 (3), 159-163.
22. Loeffler-Ragg, J.; Witsch-Baumgartner, M.; Tzankov, A.; Hilbe, W.; Schwentner, I.; Sprinzl, G. M.; Utermann, G.; Zwierzina, H. Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer 2006 Jan, 42 (1), 109-111.
23. Lee, J. W.; Soung, Y. H.; Kim, S. Y.; Nam, H. K.; Park, W. S.; Nam, S. W.; Kim, M. S.; Sun, D. I.; Lee, Y. S.; Jang, J. J.; Lee, J. Y.; Yoo, N. J.; Lee, S. H. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 2005 Apr. 15, 11 (8), 2879-2882.
24. Lynch, T. J.; Bell, D. W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R. A.; Brannigan, B. W.; Harris, P. L.; Haserlat, S. M.; Supko, J. G.; Haluska, F. G.; Louis, D. N.; Christiani, D. C.; Settleman, J.; Haber, D. A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004 May 20, 350 (21), 2129-2139.